Elan board unanimously rejects Royalty Pharma bid
DUBLIN, April 22
DUBLIN, April 22 (Reuters) - The board of Irish drugmaker Elan unanimously rejected a formal bid from Royalty Pharma on Monday, saying the U.S. investment firm's offer of $11.25 a share grossly undervalues the company.
Royalty launched a cash offer a week ago worth up to $7.3 billion, or $12 per Elan share, improving on an initial proposal to take over the Dublin-based company and the lucrative royalty rights on its main drug.
That offer depended on the outcome of a $1 billion share buyback conducted by Elan last week. Royalty lowered the bid to $11.25 a share as a result of the pricing of the buyback.
- Exclusive: Malaysia plane probe narrows on mid-air disintegration - source
- Radar showed missing plane may have turned back: Malaysia military
- Missing Malaysian jet may have disintegrated in mid-air: source |
- Malaysian plane presumed crashed; questions over false IDs |
- Merkel raps Putin as Russian forces tighten grip on Crimea |